Could Tempus RNA License Alter The Investment Case For Recursion Pharmaceuticals (RXRX)?

• Recursion Pharmaceuticals disclosed a past TxFM License Agreement with Tempus AI that grants a two year, non exclusive, oncology focused RNA model license for US$12,000,000 and access to de identified pathology records with linked clinical data.
• The combination of upfront cash and incremental oncology data directly affects how Recursion Pharmaceuticals funds its drug discovery work and refines its AI driven models.
• This section examines how Recursion Pharmaceuticals' investment narrative is shaped by this RNA model licensing cash inflow and data access.

Scan how Recursion Pharmaceuticals fits into the broader AI drug discovery story by comparing it with the hand picked 35 healthcare AI stocks that are also leaning on data rich partnerships.

Recursion Pharmaceuticals Investment Narrative Recap

To own Recursion Pharmaceuticals, you need to believe its AI driven Recursion OS and large data assets can eventually turn today’s clinical pipeline into commercial drugs and more pharma deals. The Tempus RNA model license brings US$12,000,000 of non dilutive cash and oncology data, but this looks incremental rather than a major short term catalyst.

The key near term swing factor still sits with progress in clinical programs like REC 4881 and other oncology assets, plus the pace and quality of new or expanded partnerships. The biggest risk remains a high cash burn profile, ongoing losses, and reliance on external funding if collaboration revenue or milestones do not materialize as hoped.

The Tempus agreement ties directly into one recurring theme from recent commentary. Recursion Pharmaceuticals is leaning hard on data scale and the Recursion OS 2.0 platform to improve R&D efficiency and keep attracting big pharma collaborators such as Roche & Genentech, Sanofi, Bayer, and Takeda.

Investors watching catalysts may view the TxFM License Agreement as an operational proof point for that data led story, rather than a thesis changer on its own. The extra oncology pathology data feeds into the multimodal dataset that analysts already highlight as a driver for future collaboration revenue and progression of internal oncology and rare disease trials.

Recursion Pharmaceuticals' analyst narrative points to US$220.9 million in revenue and US$35.5 million in earnings by 2028, based on a forecast 50.7% yearly revenue growth rate and a move in earnings from a loss of US$649.1 million today to that US$35.5 million profit, a swing of roughly US$684.6 million.

Uncover why Recursion Pharmaceuticals' fair value indicates a 70% potential upside to its current price, which could narrow quickly.

Exploring Other Perspectives

One alternate view on Recursion Pharmaceuticals leans much harder into the partnership story. Those bullish analysts were already penciling in revenue of about US$353.1 million and earnings of roughly US$66.8 million by 2029. You can see how a fresh Tempus RNA license could shift that optimism further, or prompt some to reassess it.

Explore 6 other Recursion Pharmaceuticals fair value estimates, including one that suggests as much as 143% upside from the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider forming your own view.

• A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• See our latest analysis for Recursion Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.

Looking For More Investment Ideas Beyond Recursion Pharmaceuticals?

Once you have a view on Recursion Pharmaceuticals, it often helps to compare it with other opportunities that fit different risk and return profiles. The Simply Wall St Screener can surface a wide mix of stocks that match your preferred income, quality, or upside characteristics.

• If you care most about resilient balance sheets and cleaner fundamentals, start with this list of solid balance sheet and fundamentals (26 results) that meet strict financial strength filters.
• Income focused investors who prioritize cash returns over headline growth can scan a set of 7 dividend fortresses that currently offer higher yields.
• For those hunting for mispriced opportunities early in their story, broaden your watchlist with a curated pool of 19 high quality undiscovered gems that pair quality metrics with relatively low attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com